Printer Friendly

ONCOGENE SCIENCE ISSUED PATENT FOR RAS ONCOGENE

 UNIONDALE, N.Y., Dec. 7 /PRNewswire/ -- Oncogene Science, Inc. (NASDAQ: ONCS) announced today that it has received a patent related to the ras oncogene. Oncogene Science is developing a diagnostic product for lung, colon and pancreatic cancer based on ras oncogene immunoassays. The new ras patent (No. 5,262,523) contains claims to antibodies specific for mutants of the ras p21 oncogene.
 Mutations of the ras oncogene have been shown to be early events in the development of cancers of the colon, lung and pancreas. Recently published reports have shown the presence of these ras mutations in plasma samples and therefore the ability to detect the presence of these mutant ras proteins in blood samples may be valuable for the early detection of malignancy. The patent entitled "Antibodies Reactive with Normal and Oncogenic Forms of the RAS p21 Protein," is the latest in a series of ras patents issue to the company.
 Commenting on the issuance of the patent Gary E. Frashier, President and Chief Executive Officer, said, "This is the most recent of a series of patents relating to the ras oncogene issued to Oncogene Science. Oncogenic mutant forms of ras are frequently found in many human cancers, notably in over half of all colon and pancreatic carcinomas. A ras oncogene diagnostic can provide an important tool for the easy detection of certain cancers."
 Oncogene Science, Inc. is a biopharmaceutical company which uses its proprietary gene transcription and oncogene-related technologies to develop products for the treatment and diagnosis of cancer and other cell control-linked diseases.
 -0- 12/7/93
 /CONTACT: Robert L. Van Nostrand, Vice President-Finance and Administration of Oncogene Science, 516-222-0023/
 (ONCS)


CO: Oncogene Science, Inc. ST: New York IN: MTC SU:

LG -- NY027 -- 1211 12/07/93 10:48 EST
COPYRIGHT 1993 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1993 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Dec 7, 1993
Words:293
Previous Article:NEWSCORP OVERSEAS LIMITED DECLARES DIVIDEND
Next Article:ONCOGENE SCIENCE ISSUED PATENT FOR TGF BETA-3
Topics:

Terms of use | Copyright © 2017 Farlex, Inc. | Feedback | For webmasters